Recruitment, Privacy, and Undue Influence
A site is recruiting for a 12-week trial of a new antidepressant in adults with major depressive disorder. The PI is a psychiatrist who treats most participants in the same clinic. The proposed recruitment plan includes: (1) the PI reviewing the electronic medical records of all patients with a depression diagnosis to identify potential participants; (2) a flyer stating 'Free guaranteed treatment - never a placebo'; (3) a $100 payment at each of 8 visits plus a $300 bonus for completing all visits; and (4) the coordinator calling patients at home after the PI identifies them. The IRB-approved protocol permits compensation but requires recruitment materials to be IRB-approved and states that pre-screening chart review requires a HIPAA waiver or authorization. Many clinic patients have limited income and rely on the PI for care.
1. What concerns should the coordinator identify before any recruitment begins?
Read the worked answer
Several issues require correction before recruitment. Reviewing charts to identify patients without an IRB-approved HIPAA waiver or patient authorization is a privacy violation. The flyer is not IRB-approved and is misleading if the trial is placebo-controlled; 'free guaranteed treatment' promises benefit and omits alternatives. A $300 completion bonus on top of $100 per visit may be undue influence for low-income patients, especially when the PI controls their care. The PI's dual role as treating psychiatrist and investigator creates therapeutic misconception and pressure; home calls from the coordinator after PI identification also raise privacy concerns. The coordinator should not begin calls or post the flyer. Instead, confirm the recruitment materials and pre-screening plan are IRB-approved, confirm HIPAA authorization or waiver, and ask the IRB to review the compensation and consent language. Consider having a non-treating clinician obtain consent.
2. How should the recruitment plan be revised to meet privacy and voluntariness requirements?
Read the worked answer
The coordinator should revise the flyer to state the trial's purpose, placebo possibility, time commitment, and that participation is voluntary; remove 'guaranteed' and 'never a placebo' unless accurate. Submit it to the IRB. For pre-screening, use only the IRB-approved method: a partial HIPAA waiver, an authorization, or clinician referral with patient permission. If a waiver is not in place, ask clinic staff to hand patients an IRB-approved information sheet so interested patients can call the site, rather than the site calling them. Review the payment schedule with the IRB; a completion bonus may be acceptable if not coercive, but prorated payment for time and travel is safer. Train staff on avoiding pressure. Document all approvals before any contact.
3. How should consent be handled when the PI is also the patient's treating psychiatrist?
Read the worked answer
When a patient is also the PI's clinic patient, consent should ideally be obtained by someone not involved in their treatment. If the PI must consent, the discussion must state the dual role, that declining will not affect care, and that alternative treatments exist. Use a private room, allow time, and avoid having clinic staff imply the patient owes the doctor participation. Screen for financial pressure: explain payments are for time and travel, not a reason to join, and do not offer the completion bonus as a surprise. Ask the patient to explain the study in their own words. Document the voluntariness discussion. If a patient says they feel they cannot refuse, do not enroll and note the reason. The coordinator should also monitor for clustering of vulnerable patients and discuss safeguards with the IRB.